Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. (Nasdaq: SMTI) is a medical technology company that regularly issues news and updates about its surgical, chronic wound and skin-focused business. Company announcements describe a portfolio of surgical tissue repair and advanced wound care products, including CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® Extracellular Matrix and several biologic bone and soft tissue matrices.
News releases often cover developments in Sanara’s commercial strategy and product adoption. For example, the company has reported on growth in soft tissue repair product sales driven by increased demand for CellerateRX Surgical and BIASURGE, expansion into additional medical facilities and the development of an independent distribution network in U.S. markets. Updates also include information on contracts and partnerships, such as an Innovative Technology contract from Vizient® Inc. for BIASURGE, which provides Vizient’s healthcare facility customers with access to the product at contracted pricing and pre-negotiated terms.
Sanara’s news flow includes financial result announcements, where it discusses segment performance, revenue trends and the impact of its strategic realignment. The company has reported the discontinuation of its Tissue Health Plus (THP) operations and the classification of THP as discontinued operations, emphasizing a renewed focus on its core surgical business. Management commentary in these releases outlines priorities related to operating efficiency and capital allocation toward surgical products.
In addition, Sanara issues updates on its product pipeline and alliances, such as its exclusive U.S. license and distribution agreement for OsStic™ Synthetic Injectable Structural Bio-Adhesive and related internal fixation technology. Investors and observers can use the SMTI news page to follow product-related announcements, financial disclosures, strategic decisions and conference participation updates that the company provides through press releases.
Sanara MedTech (SMTI) reported strong Q4 2024 financial results with net revenue increasing 49% year-over-year to $26.3 million. Full-year 2024 revenue grew 33% to $86.7 million.
Q4 highlights include:
- Gross profit rose 51% to $24.1 million with 91% margin
- Operating loss of $0.4 million compared to $0.2 million loss in Q4 2023
- Net loss of $1.7 million versus $0.3 million loss in Q4 2023
- Adjusted EBITDA of $0.9 million, up from $0.4 million
The growth was primarily driven by increased sales of soft tissue repair products, particularly CellerateRX Surgical and BIASURGE. The company plans to invest $7.5-10.0 million in Tissue Health Plus segment in H1 2025, with a pilot program launch expected in Q2. As of December 31, 2024, Sanara had $15.9 million cash and $30.5 million in debt obligations.
Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound and skincare markets, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 25, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day to discuss the results for the quarter and year ended December 31, 2024. Investors can join via phone (toll-free: 888-506-0062, international: 973-528-0011, access code: 904042) or watch the live webcast on the company's website. A replay will be available through April 08, 2025.
Sanara MedTech (NASDAQ: SMTI) has announced an exclusive license and distribution agreement with Biomimetic Innovations (BMI), alongside a minority investment of up to €8.0 million for approximately 12.5% equity stake in BMI. The company has made an initial €4.0 million investment, with the remaining €4.0 million contingent on achieving specific milestones.
The agreement grants Sanara exclusive U.S. rights to market, sell, and distribute OsStic®, a synthetic injectable structural bio-adhesive bone void filler, along with related delivery technology. OsStic received FDA Breakthrough Device Designation in December 2023 for periarticular fractures treatment. The technology addresses an estimated 100,000+ annual U.S. procedures.
The five-year agreement includes automatic renewal options. Market introduction is anticipated in Q1 2027, complementing Sanara's existing surgical portfolio.
Sanara MedTech (NASDAQ: SMTI) has announced key changes to its executive leadership team effective January 15, 2025. Elizabeth Taylor has been appointed as Chief Financial Officer, succeeding Michael McNeil, who transitions to the roles of Chief Accounting Officer and Chief Administrative Officer.
Taylor brings over 25 years of financial experience, including previous positions as CFO at Imbed Biosciences, COO of multiple hedge funds, and investment team member at a private equity firm. She most recently served as CFO at Imbed Biosciences from 2023 to 2025, where she managed budgeting, forecasting, and financial analysis. Her background includes founding Burnett Taylor Consulting, serving as COO at PioneerPath Capital and Tala Investments, and working at Thomas H. Lee Partners.
Ron Nixon, Sanara's Executive Chairman and CEO, emphasized that Taylor's combination of industry and Wall Street experience will complement their existing finance and accounting teams as they continue their growth phase in the surgical, chronic wound, and skincare markets.
Sanara MedTech Inc. (SMTI) reported strong preliminary Q4 2024 results with expected net revenue between $25.7-26.2 million, representing a 45-48% year-over-year increase. Full-year 2024 revenue is projected at $86.0-86.5 million, up 32-33% from 2023.
Growth was primarily driven by increased sales of soft tissue repair products, particularly CellerateRX Surgical Activated Collagen and BIASURGE. The company benefited from temporary BIASURGE sales surge ($1.8 million) due to industry-wide IV fluid shortages following Hurricane Helene, expected to normalize in Q1 2025.
As of December 31, 2024, SMTI maintained $15.9 million in cash, $30.5 million in debt obligations, and $24.5 million in available borrowing capacity. The company filed 11 provisional patent applications in 2024 for antimicrobial technologies and hydrolyzed collagen innovations.
Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound, and skincare markets, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place at The Lotte New York Palace from December 3-5, 2024. Ron Nixon, the Company's Chairman and CEO, will deliver a presentation to investors on December 4 at 11:50 a.m. Eastern Time. Presentation materials will be available on the company's investor relations website before the event, along with a live audio webcast and replay option.
Sanara MedTech (NASDAQ: SMTI) reported its Q3 2024 results, marking its twelfth consecutive record net revenue quarter. Net revenue increased 35% year-over-year to $21.7 million. The company reported a net loss of $2.9 million, compared to a $1.1 million loss in Q3 2023. The company expanded its distribution network to 300+ distributors and its products are now sold in over 1,200 facilities across 34 states. Sanara invested $5.0 million for a 6.64% stake in ChemoMouthpiece and secured exclusive U.S. distribution rights for their cryotherapy device.
Sanara MedTech (NASDAQ: SMTI), a medical technology company focused on surgical, chronic wound and skincare markets, has scheduled its Q3 2024 earnings release for November 12, 2024. The company will host a conference call on November 13, 2024, at 9:00 a.m. Eastern Time. Investors can join via phone (toll-free: 888-506-0062, international: 973-528-0011, access code: 373459) or webcast through the company's website. A replay will be available through November 27, 2024.
Sanara MedTech Inc. (NASDAQ: SMTI) and InfuSystem Holdings, Inc. have announced an exclusive U.S. distribution agreement with ChemoMouthpiece, , along with a minority investment. The deal involves:
1. SI Healthcare Technologies, a 50/50 joint venture between Sanara and InfuSystem, becoming the exclusive U.S. distributor of ChemoMouthpiece's kits.
2. Sanara investing $5 million for a 6.6% ownership in ChemoMouthpiece.
3. Distribution of a 510(k) cleared cryotherapy device to reduce oral mucositis in chemotherapy patients.
4. A market opportunity estimated at over $600 million, targeting 500,000 - 1,000,000 annual patients.
5. Potential for cost reductions in oncology treatment centers and improved patient quality of life.
Sanara MedTech Inc. (NASDAQ: SMTI) reported its Q2 2024 results, marking its eleventh consecutive record revenue quarter. The company achieved $20.2 million in sales, a 28% increase from Q2 2023. Despite this growth, Sanara reported a net loss of $3.5 million, compared to a $1.9 million loss in Q2 2023. The increased loss was primarily due to higher SG&A costs, executive separation expenses, and acquisition costs.
Positive developments include Adjusted EBITDA of $0.6 million, improved from -$0.3 million in Q2 2023, and expanded market presence with products sold in over 1,100 facilities across 34 states. Sanara also secured a $55 million non-dilutive term loan to support growth initiatives and made key executive appointments to strengthen its management team.